Japan Vaccine Co., a joint venture created by an equal investment between Daiichi Sankyo Inc. and GlaxoSmithKline K.K., started operations on July 2.
Japan Vaccine, based in Tokyo, will hold all development and marketing rights for prophylactic vaccines owned by both of its parent companies and perform clinical development, marketing and sales activities in Japan.
Among its main products will be Cervarix (cervical cancer); Rotarix (rotavirus); seasonal flu vaccine; mumps vaccine; diphtheria vaccine; and measles vaccine.
At the start of operations, Japan Vaccine will only handle its parent companies’ existing vaccines but will soon add vaccine candidates currently in development that are expected to be approved.
Japan Vaccine intends to utilize both of its parent companies to protect a wide range of Japanese patients from infectious diseases as a highly specialized vaccine business.
The new company will be capitalized with 100 million yen ($1.2 million) and will have approximately 220 employees.
- « Prev
- Next »